ArticlePloS one2024

Sintilimab plus chemotherapy with or without bevacizumab biosimilar IBI305 in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapy: A China-based cost-effectiveness analysis.

Juan Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.